Eisai Co., Ltd (OTCMKTS:ESALY) Receives Consensus Recommendation of “Hold” from Brokerages

Eisai Co., Ltd (OTCMKTS:ESALY) has received a consensus recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $57.00.

Several brokerages recently commented on ESALY. Zacks Investment Research raised shares of Eisai from a “hold” rating to a “buy” rating and set a $57.00 price objective for the company in a research note on Tuesday, October 8th. Daiwa Capital Markets downgraded shares of Eisai from a “neutral” rating to a “sell” rating in a research note on Tuesday, September 17th. Jefferies Financial Group began coverage on shares of Eisai in a research note on Tuesday, September 24th. They issued a “buy” rating for the company. Finally, Citigroup raised shares of Eisai from a “sell” rating to a “neutral” rating in a research note on Monday, August 5th.

Shares of OTCMKTS:ESALY opened at $51.31 on Friday. The company has a market cap of $14.66 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 2.02 and a beta of 0.26. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.91 and a quick ratio of 1.66. The firm has a 50 day simple moving average of $50.52 and a 200 day simple moving average of $54.86. Eisai has a one year low of $48.52 and a one year high of $96.16.

Eisai (OTCMKTS:ESALY) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.69 EPS for the quarter. The business had revenue of $1.40 billion during the quarter. Eisai had a net margin of 11.33% and a return on equity of 11.32%. As a group, analysts expect that Eisai will post 2.38 EPS for the current year.

Eisai Company Profile

Eisai Co, Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia.

Read More: High-Yield Dividend Stocks

Analyst Recommendations for Eisai (OTCMKTS:ESALY)

Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit